Elysium Therapeutics Tackles Fentanyl Crisis with SOOPR™ Tech
Elysium Therapeutics Innovates Solutions Against Fentanyl Overdoses
Elysium Therapeutics is making significant strides in combating the devastating effects of opioid overdoses, particularly focusing on the challenges posed by fentanyl. This emerging biopharmaceutical company is committed to developing treatments specifically designed to reverse overdoses caused by synthetic opioids, especially oral fentanyl. Recently, they held a webcast aimed at educating investors and pharmaceutical professionals about the urgent need for new overdose rescue solutions tailored to the properties of synthetic opioids.
Understanding the Fentanyl Challenge
During the webcast titled "Innovating Solutions to Combat Fentanyl Rebound," CEO Greg Sturmer highlighted the serious limitations of current opioid antagonists such as Narcan and Opvee. These short-acting medications often fail to manage synthetic opioid overdoses effectively, as studies show that a significant percentage of overdose victims—between 20% and 45%—experience a re-narcotization event even after being treated with naloxone.
The Critical Need for Long-Acting Solutions
Sturmer explained, "When fentanyl is ingested orally, it can lead to a perilous state where respiration may be suppressed for a prolonged period, ranging from six to eight hours. However, the duration of action for most rescue medications is limited to about 30 minutes. This discrepancy contributes to the frightening statistics where nearly half of patients initially revived can relapse into overdose, potentially resulting in serious consequences such as hypoxic brain injuries or death." This grim reality illustrates the necessity for more effective interventions.
Elysium's SOOPR™ Technology
To tackle these critical issues, Elysium has developed its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology. This innovative approach aims to provide faster-acting and longer-lasting overdose protection, with an estimated duration of effect lasting up to 24 hours. Unlike traditional intranasal methods, SOOPR is administered intramuscularly, ensuring a more consistent and effective dosage, thereby enhancing the chances of successful overdose reversal in high-pressure scenarios.
A Specialized Approach for a Growing Crisis
Sturmer pointed out that synthetic opioids have tragically become the leading cause of mortality among adults aged 18 to 45 in the U.S. As a response to this growing threat, the need for an efficient, long-duration reversal agent like SOOPR is critical. Elysium is positioning itself to expedite the clinical development of SOOPR, with the aim of making this life-saving technology available in the market within the next few years.
About SOOPR™
SOOPR is a pioneering rapid-onset, long-acting agent specifically crafted to counteract overdoses from synthetic opioids, including those from oral fentanyl. Using a proprietary formulation that combines naloxone with enhanced pharmacokinetics, SOOPR promises not only to restore breathing effectively but also to maintain opioid blockade for an extended period. By utilizing this advanced technology, Elysium is helping to address the urgent needs of first responders and healthcare providers dealing with the escalating opioid crisis.
About Elysium Therapeutics
Elysium Therapeutics is dedicated to revolutionizing the way opioid overdoses are managed, focusing on creating effective solutions that ensure safety and efficacy. The company aims to establish new industry standards by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, including the groundbreaking SOOPR technology. By targeting the limitations associated with existing rescue agents, Elysium hopes to significantly reduce the incidence of opioid overdose fatalities, enhancing the quality of life for those affected by opioid-use disorder. Additionally, Elysium is expanding its portfolio to include oral-overdose protected (O2P™) hydrocodone for acute pain management, further showcasing its commitment to addressing the multifaceted challenges posed by opioids.
Frequently Asked Questions
What is SOOPR™ technology?
SOOPR™ is a long-acting rescue agent specifically designed to prevent and reverse overdoses from synthetic opioids, providing protection for up to 24 hours.
Why is there a need for new opioid overdose treatments?
Current treatments often fail due to short duration of action, resulting in high rates of re-narcotization and potential fatalities.
Who is behind Elysium Therapeutics?
Elysium Therapeutics is an emerging biopharmaceutical company dedicated to creating treatments aimed at reversing opioid overdoses and establishing safer standards in the opioid industry.
What is the target market for SOOPR™?
SOOPR™ is especially crucial for adults aged 18 to 45, who represent the highest risk group for synthetic opioid overdoses.
How does Elysium plan to advance SOOPR's development?
Elysium is rapidly planning to advance the SOOPR clinical program to bring the technology to market in the next two to three years.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
